HRMY
Harmony Biosciences HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.89B
P/E Ratio
11.72
EPS
$2.78
Beta
0.96
52W High
$40.87
52W Low
$25.52
50-Day MA
$28.91
200-Day MA
$32.97
Dividend Yield
—
Profit Margin
18.30%
Forward P/E
9.65
PEG Ratio
—
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
| Revenue (TTM) | $868.45M |
| Gross Profit (TTM) | $670.11M |
| EBITDA | $233.80M |
| Operating Margin | 15.80% |
| Return on Equity | 20.70% |
| Return on Assets | 11.50% |
| Revenue/Share (TTM) | $15.11 |
| Book Value | $15.07 |
| Price-to-Book | 2.12 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 1.416 |
| EV/EBITDA | 4.82 |
| Quarterly Earnings Growth (YoY) | -55.00% |
| Quarterly Revenue Growth (YoY) | 21.10% |
| Shares Outstanding | $57.87M |
| Float | $51.68M |
| % Insiders | 11.68% |
| % Institutions | 94.97% |
Historical Volatility
HV 10-Day
49.97%
HV 20-Day
38.06%
HV 30-Day
36.18%
HV 60-Day
51.56%
HV Rank
54.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($43.00 target)
2
Strong Buy4
Buy4
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/5/2026